Shelter Pharma (543963) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
1 Sep, 2025Executive summary
Audited standalone financial results for the half year and year ended March 31, 2025, were approved by the Board on May 29, 2025, with an unmodified audit opinion.
Internal and secretarial auditors were appointed for FY 2025-26 and for a five-year term, respectively.
Financial highlights
Revenue from operations for FY 2025 was ₹5,066.02 lakh, up from ₹4,002.29 lakh in FY 2024.
Net profit for FY 2025 was ₹723.74 lakh, compared to ₹620.02 lakh in FY 2024.
EPS for FY 2025 was ₹6.26, up from ₹5.36 in FY 2024.
Total equity and liabilities as of March 31, 2025, stood at ₹4,833.55 lakh, up from ₹3,791.48 lakh a year earlier.
Cash and cash equivalents at year-end were ₹341.99 lakh, down from ₹503.98 lakh at the previous year-end.
Outlook and guidance
The company continues to operate as a going concern, with no material uncertainties identified by auditors.
Latest events from Shelter Pharma
- Revenue and net profit rose in FY18; profits were retained and no dividend recommended.543963
Q4 17/18 - Revenue declined, but FY19 net profit and EPS improved; no dividend was recommended.543963Q4 18/19
- Revenue and PAT rose in FY20 as factory expansion advanced; Rs 3 crore of advances were written off.543963Q4 19/20
- COVID disruption cut sales as FY21 profit fell; ₹30 lakh of old advances was written off.543963Q4 20/21
- FY22 revenue and profit rose sharply, while COVID disruptions remained a sales risk.543963Q4 21/22
- FY23 profit rose, while receivables climbed and an IPO of up to ₹350m advanced.543963Q4 22/23
- Strong revenue and profit growth, full utilization of raised funds, and clean audit opinion.543963Q4 25/26
- Revenue and profit increased year-over-year, with all raised funds used as intended.543963Q2 25/26
- Revenue and net profit grew year-over-year, with EPS rising to ₹3.06.543963Q2 24/25